Table 1. Selected clinical... | American Society of Hematology

Table 1.

Selected clinical characteristics and outcomes of 28 patients with BNS treated with ibrutinib

ID	Age WM diagnosis, y	Sex	Prior WM therapy	Age BNS diagnosis, y	Prior BNS therapy	Dose, mg	Best response			Stopped ibrutinib	EFS, mo*
ID	Age WM diagnosis, y	Sex	Prior WM therapy	Age BNS diagnosis, y	Prior BNS therapy	Dose, mg	Symptomatic	Radiologic	Cytologic	Stopped ibrutinib	EFS, mo*
1	56	M	No	65	Yes	560	Improved	Improved	NA	No	23
2	60	F	No	60	No	560	Unchanged	Unchanged	Cleared	Yes	5
3	61	F	Yes	76	No	560	Improved	Improved	NA	No	23
4	72	M	Yes	78	No	420	Improved	Resolved	NA	No	27
5	48	F	No	49	Yes	560	Improved	Improved	Cleared	No	10
6	73	F	Yes	76	Yes	560	Unchanged	Improved	Cleared	No	4
7	65	M	Yes	75	Yes	560	Improved	Improved	Persistent	No	48
8	63	M	No	64	No	560	Improved	Improved	Persistent	No	6
9	61	F	No	61	No	560	Improved	Improved	Persistent	No	6
10	72	M	No	72	Yes	560	Improved	Improved	NA	No	3
11	53	M	Yes	65	Yes	420	Improved	Unchanged	Cleared	Yes	4
12	62	M	No	62	No	420	Improved	Unchanged	Persistent	No	13
13	56	M	Yes	65	No	420	Unchanged	Improved	NA	No	22
14	56	M	Yes	63	Yes	560	Resolved	NA	Cleared	No	10
15	52	M	Yes	78	Yes	420	Improved	NA	Cleared	Yes	1
16	49	F	No	50	Yes	560	Improved	NA	Persistent	No	8
17	55	F	Yes	59	No	560	Improved	NA	Persistent	Yes	4
18	64	M	No	64	Yes	420	Resolved	Resolved	Persistent	No	11
19	38	M	Yes	38	Yes	420	Resolved	Improved	NA	No	10
20	61	F	No	61	Yes	420	Unchanged	Improved	Persistent	Yes	8
21	67	F	Yes	71	No	420	Resolved	NA	NA	No	8
22	60	M	Yes	67	Yes	420	Resolved	Improved	Persistent	No	33
23	61	M	Yes	76	No	420	Improved	NA	Cleared	No	15
24	42	F	Yes	60	Yes	420	Improved	NA	NA	No	13
25	76	M	No	80	Yes	420	Improved	NA	NA	No	11
26	53	F	Yes	66	Yes	420	Improved	NA	Cleared	No	8
27	80	F	Yes	81	No	420	Improved	NA	NA	No	4
28	57	M	Yes	66	Yes	560	Improved	Improved	NA	No	13

ID	Age WM diagnosis, y	Sex	Prior WM therapy	Age BNS diagnosis, y	Prior BNS therapy	Dose, mg	Best response			Stopped ibrutinib	EFS, mo*
ID	Age WM diagnosis, y	Sex	Prior WM therapy	Age BNS diagnosis, y	Prior BNS therapy	Dose, mg	Symptomatic	Radiologic	Cytologic	Stopped ibrutinib	EFS, mo*
1	56	M	No	65	Yes	560	Improved	Improved	NA	No	23
2	60	F	No	60	No	560	Unchanged	Unchanged	Cleared	Yes	5
3	61	F	Yes	76	No	560	Improved	Improved	NA	No	23
4	72	M	Yes	78	No	420	Improved	Resolved	NA	No	27
5	48	F	No	49	Yes	560	Improved	Improved	Cleared	No	10
6	73	F	Yes	76	Yes	560	Unchanged	Improved	Cleared	No	4
7	65	M	Yes	75	Yes	560	Improved	Improved	Persistent	No	48
8	63	M	No	64	No	560	Improved	Improved	Persistent	No	6
9	61	F	No	61	No	560	Improved	Improved	Persistent	No	6
10	72	M	No	72	Yes	560	Improved	Improved	NA	No	3
11	53	M	Yes	65	Yes	420	Improved	Unchanged	Cleared	Yes	4
12	62	M	No	62	No	420	Improved	Unchanged	Persistent	No	13
13	56	M	Yes	65	No	420	Unchanged	Improved	NA	No	22
14	56	M	Yes	63	Yes	560	Resolved	NA	Cleared	No	10
15	52	M	Yes	78	Yes	420	Improved	NA	Cleared	Yes	1
16	49	F	No	50	Yes	560	Improved	NA	Persistent	No	8
17	55	F	Yes	59	No	560	Improved	NA	Persistent	Yes	4
18	64	M	No	64	Yes	420	Resolved	Resolved	Persistent	No	11
19	38	M	Yes	38	Yes	420	Resolved	Improved	NA	No	10
20	61	F	No	61	Yes	420	Unchanged	Improved	Persistent	Yes	8
21	67	F	Yes	71	No	420	Resolved	NA	NA	No	8
22	60	M	Yes	67	Yes	420	Resolved	Improved	Persistent	No	33
23	61	M	Yes	76	No	420	Improved	NA	Cleared	No	15
24	42	F	Yes	60	Yes	420	Improved	NA	NA	No	13
25	76	M	No	80	Yes	420	Improved	NA	NA	No	11
26	53	F	Yes	66	Yes	420	Improved	NA	Cleared	No	8
27	80	F	Yes	81	No	420	Improved	NA	NA	No	4
28	57	M	Yes	66	Yes	560	Improved	Improved	NA	No	13

NA, not available.

Toxicity, progression, or death.